STRATUMfiling intelligence๐Ÿ‡ฎ๐Ÿ‡ณ Indian private portal

SPRY

ARS Pharmaceuticals, Inc.
CIK 0001671858 ยท EDGAR โ†—
cleanelevatedtriggeredno dataplanned
69.9
composite ยท 3 signals ยท ELEVATED

Every card below shows the score and the exact filing data it was computed from โ€” no unexplained numbers. Some signals (P-02, P-03, P-08, P-09, P-10, P-11) pull live documents from SEC EDGAR the first time you view this company; a few of those (P-03, P-10, P-11) use AI to read the filing text, but every AI claim must quote the actual document verbatim or it's discarded โ€” never a guess.

Chat with this filing โ†’

Ask follow-up questions about the latest 10-K, with citations verified against the actual text. No account needed.

Investigation memo โ€” generate one โ†’

Run the bounded investigation agent โ€” reads this company's signals and writes a short, cited summary.

Signals

P-01 ยท FY 2025-12-31 ยท ELEVATED47.2

Earnings quality

Beneish M-Score -1.85 in the elevated zone
trend: flat
Trend
Source: 10-K on SEC.gov (filed 2026-03-09) โ†—
Evidence โ€” inputs and thresholds
{
  "m_score": -1.848,
  "threshold": -1.78,
  "ratios": {
    "DSRI": 3.28,
    "GMI": 1,
    "AQI": 2.734,
    "SGI": 0.945,
    "DEPI": 1,
    "SGAI": 3.396,
    "LVGI": 6.196,
    "TATA": -0.001
  },
  "defaulted_to_neutral": [
    "GMI",
    "DEPI"
  ],
  "sloan_accruals": -0.0013,
  "inputs": {
    "revenue_t": 84278000,
    "revenue_t1": 89149000,
    "total_assets_t": 327652000,
    "net_income_t": -171298000,
    "cfo_t": -170866000
  },
  "stale": false,
  "latest_filing_period": "2025-12-31",
  "source": {
    "url": "https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/0001193125-26-097478-index.htm",
    "form": "10-K",
    "filed": "2026-03-09"
  }
}
P-05 ยท FY 2024-12-31 ยท ELEVATED80.1

Tax arbitrage

ETR 3.5% vs 21% statutory โ€” gap persistent across 1 of 1 years
trend: flat
Trend
Source: 10-K on SEC.gov (filed 2026-03-09) โ†—
Evidence โ€” inputs and thresholds
{
  "etr_by_year": {
    "2024-12-31": 0.0348
  },
  "statutory_rate": 0.21,
  "gap_by_year": {
    "2024-12-31": 0.1752
  },
  "note": "Low ETR can be fully legitimate; this flags persistence + magnitude for review.",
  "stale": false,
  "latest_filing_period": "2025-12-31",
  "source": {
    "url": "https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/0001193125-26-097478-index.htm",
    "form": "10-K",
    "filed": "2026-03-09"
  }
}
P-12 ยท FY 2025-12-31 ยท ELEVATED36.2

Restatement predictor

F-Score 1.09 โ€” misstatement risk 1.1x the base rate
trend: flat
Trend
Source: 10-K on SEC.gov (filed 2026-03-09) โ†—
Evidence โ€” inputs and thresholds
{
  "f_score": 1.086,
  "probability": 0.00402,
  "components": {
    "rsst": -0.0013,
    "drec": 0.0506,
    "dinv": 0.0616,
    "soft": 0.8664,
    "dcs": -0.2473,
    "droa": -0.5456,
    "issue": 0
  },
  "model": "Dechow et al. 2011, Model 1 (simplified RSST)",
  "thresholds": {
    "elevated": 1,
    "triggered": 1.85
  },
  "stale": false,
  "latest_filing_period": "2025-12-31",
  "source": {
    "url": "https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/0001193125-26-097478-index.htm",
    "form": "10-K",
    "filed": "2026-03-09"
  }
}